The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss
The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss
复制标题
DOI：
10.1177/014556131109000506
复制
发表时间：
2011-05-01
影响因子：
1.3
通讯作者：
Varshey, Saurabh
中科院分区：
文献类型：
--
作者：
Chauhan, Rajeev Singh;Saxena, Ravinder Kumar;Varshey, Saurabh
在监测药物所致听力损失的患者时，大多数测听评估仅限于0.25至8 kHz的频率范围。然而，这种测试无法检测到已经在10至20千赫超高频下听力损失的患者的耳毒性。对超高频耳毒性的认识可能会导致药物方案的改变，以防止进一步的损害。我们对105名接受潜在耳毒性药物-庆大霉素、阿米卡星或顺铂-的患者进行了前瞻性研究，以评估超高频测听在检测全身性药物所致听力损失中的价值。我们发现，将听力测量扩展到超高频范围导致了大量听力损失的检测，否则这些听力损失就会被遗漏。
In monitoring patients for drug-induced hearing loss, most audiometric evaluations are limited to the range of frequencies from 0.25 to 8 kHz. However, such testing would fail to detect ototoxicity in patients who have already experienced hearing loss in the ultrahigh frequencies from 10 to 20 kHz. Awareness of ultrahigh-frequency ototoxicity could lead to changes in a drug regimen to prevent further damage. We conducted a prospective study of 1 05 patients who were receiving a potentially ototoxic drug-either gentamicin, amikacin, or cisplatin-to assess the value of ultrahigh-frequency audiometry in detecting systemic drug-induced hearing loss. We found that expanding audiometry into the ultrahigh-frequency range led to the detection of a substantial number of cases of hearing loss that would have otherwise been missed.